NASDAQ$CNTA
Centessa Pharmaceuticals plc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Centessa Pharmaceuticals reported a net loss of $50.3 million for the second quarter of 2025 driven by increased R&D spending on its OX2R agonist program.
The company recorded no revenue in the quarter while R&D expenses rose to $42.7 million, primarily from advancing ORX750 and ORX142. Cash, cash equivalents and investments totaled $404.1 million, expected to fund operations into mid-2027. Net loss per share was $0.38 on 133.7 million weighted average shares.
- Q2 2025 net loss of $50.3 million compared to $43.8 million in Q2 2024, reflecting higher clinical development costs.
- R&D expenses increased 30% year-over-year to $42.7 million, focused on OX2R agonist franchise including ORX750 Phase 2a and ORX142 Phase 1 initiation.
- Cash position of $404.1 million provides runway into mid-2027 to support ongoing clinical programs.
- Discontinuation of LB101 and SerpinPC programs allows capital reallocation to core orexin agonist pipeline.
Headline financials
Revenue & EPS history
Centessa · Revenue · Quarterly
$0
Forward guidance
Existing cash, cash equivalents and investments of $404.1 million expected to fund operations into mid-2027.
Tailwinds
- Strong balance sheet supports advancement of OX2R agonist programs
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+1.0%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+4.0%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+19.4%
Q2 2024
Best reaction
-14.6%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -0.1% | -0.3% | +0.3% | |
| Q4 2025 | -4.2% | +6.1% | +45.9% | |
| Q3 2025 | -5.2% | -5.9% | +26.0% | |
| Q1 2025 | -1.2% | -1.6% | -0.6% | |
| Q4 2024 | -4.9% | -12.3% | -18.2% | |
| Q3 2024 | +8.1% | -4.4% | +0.8% | |
| Q2 2024 | +19.4% | +18.5% | +43.1% | |
| Q1 2024 | +0.8% | -1.1% | +8.1% | |
| Q4 2023 | -0.2% | +2.1% | -19.6% | |
| Q3 2023 | +6.8% | +13.4% | +7.1% | |
| Q2 2023 | +3.6% | -4.2% | +1.0% | |
| Q1 2023 | +0.2% | +0.9% | -0.4% | |
| Q4 2022 | -1.3% | -3.1% | +21.0% | |
| Q3 2022 | +5.3% | +4.7% | +15.1% | |
| Q2 2022 | -14.6% | -22.4% | -19.4% | |
| Q1 2022 | +2.0% | -15.7% | -21.1% | |
| Q4 2021 | -0.2% | +9.6% | -3.0% | |
| Q3 2021 | +2.5% | +9.3% | -9.9% | |
| Q1 2021 | +1.7% | +3.4% | +2.1% | |
| Q2 2021 | +1.7% | +3.4% | +2.1% | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro